
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is advancing its clinical-stage pipeline focused on neurodegenerative diseases, with a particular emphasis on therapeutics and diagnostics targeting misfolded proteins. The positive outlook is bolstered by significant developments such as the upcoming EVOKE trial for AD patients, which could dramatically enhance interest in the NLRP3 program, and encouraging results from the PD active immunotherapy ACI-7104.056, which has exhibited a 20-fold increase in antibodies against pathogenic variants of alpha-synuclein, thereby positioning the company favorably within a growing treatment landscape for Alzheimer’s disease.
Bears say
AC Immune SA reported a net operating loss of CHF 16.2 million for the quarter, indicating financial distress and potential challenges in sustaining operations. The company is exposed to significant industry risks, including the possibility of adverse clinical trial outcomes, regulatory hurdles, and the complexities of navigating price-sensitive markets for its product candidates. These factors contribute to a precarious financial outlook, raising concerns about the company's ability to effectively advance its pipeline of therapies and diagnostic products targeting neurodegenerative diseases.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares